Investors

Press Releases

Date Title View
Toggle Summary Tetraphase Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Highlights
WATERTOWN, Mass. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the
View HTML
Toggle Summary Tetraphase Pharmaceuticals Receives Positive CHMP Opinion for Xerava™ (eravacycline) as a Treatment for Complicated Intra-Abdominal Infections
WATERTOWN, Mass. , July 27, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that the Committee for
View HTML
Toggle Summary Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass. , July 12, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Tetraphase's Compensation
View HTML
Toggle Summary Tetraphase Pharmaceuticals Announces Data from a Pooled Analysis of IGNITE1 and IGNITE4 Phase 3 Trials Evaluating Eravacycline in Complicated Intra-Abdominal Infections at the ASM Microbe 2018 Annual Meeting
Eravacycline Global Surveillance and TP-6076 Data Also Highlighted WATERTOWN, Mass. , June 11, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening
View HTML
Toggle Summary Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass. , June 08, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Tetraphase's Compensation
View HTML
Toggle Summary Tetraphase Pharmaceuticals Announces Everest Medicines’ Submission of an Investigational New Drug Application for Eravacycline in Complicated Intra-Abdominal Infection to the China Food and Drug Administration
WATERTOWN, Mass. , June 04, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that Everest Medicines Limited
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present Eravacycline and TP-6076 Data at ASM Microbe 2018
– Four Abstracts Selected for Poster Presentations – – Presentations Include New Eravacycline Pooled Analysis of IGNITE 1 and IGNITE4 and Data Highlighting the Pre-Clinical Activity of TP-6076 – WATERTOWN, Mass. , May 21, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc.
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at the UBS Global Healthcare Conference
WATERTOWN, Mass. , May 09, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant infections, announced today that its corporate presentation will be webcast live at the UBS
View HTML
Toggle Summary Tetraphase Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights
WATERTOWN, Mass. , May 03, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the first
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present Data at the 38th Annual Meeting of the Surgical Infection Society
WATERTOWN, Mass. , April 19, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced two data presentations at the
View HTML